4 research outputs found
Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report
BACKGROUND: The use of atypical antipsychotics in schizophrenic patients has been associated with a risk of weight gain. Similarly, recovery from depression is often followed by improved appetite, greater food intake and potential increase in weight. CASE PRESENTATION: A Caucasian 33-year-old schizophrenic female patient was being treated with 6 mg/day of risperidone and 15 mg/day of clorazepate. She developed depressive symptomatology and 40 mg/day of fluoxetine was gradually added to her treatment regimen for about 9 months. After the remission of depression, and the discontinuation of fluoxetine, she experienced an increase in appetite and subsequently excessive weight gain of 52 kg. Re-administration of fluoxetine did not reverse the situation. The patient developed diabetes mellitus, which was successfully controlled with metformin 1700 mg/day. The addition at first of orlistat 360 mg/day and later of topiramate 200 mg/day has helped her to lose a significant part of the weight gained (30 kg). CONCLUSION: The case suggests a probable association between the remission of depressive symptomatology and weight gain in a schizophrenic patient
Psychiatric admission as a risk factor for posttraumatic stress disorder
Psychiatric hospitalization poses a risk for Posttraumatic Stress
Disorder (PTSD), partly because of coercion. However, the role of legal
status is less clear, while factors like insight, exposure to violence
and affective disorders have not been addressed adequately. The present
study aims at assessing PTSD rates after hospitalization and evaluating
the potential role of these factors. 98 inpatients were assessed for
PTSD, insight, main diagnosis, adverse events during hospitalization and
legal status. Assessment took place at discharge (T1) and three months
later (T2). Three months after discharge, 74.2% of patients with
affective disorders met symptom-criteria for PTSD. Voluntarily
hospitalized patients had more severe PTSD-symptoms. This relation
vanished after controlling for affective disorders. The latter, as well
as exposure to violence were the most significant risk factors at T2.
Female gender, marital status (not married) and employment status (not
employed), were additional risk factors at T1, while involuntary
medication had a negative effect on PTSD-symptoms. Voluntarily
hospitalized patients are more vulnerable to PTSD, due to higher rates
of affective disorders. Females suffering from affective disorders who
are not married and not employed should be monitored for PTSD symptoms
during and after hospitalization, especially if exposed to violence
Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report
Background: The use of atypical antipsychotics in schizophrenic patients
has been associated with a risk of weight gain. Similarly, recovery from
depression is often followed by improved appetite, greater food intake
and potential increase in weight.
Case presentation: A Caucasian 33-year-old schizophrenic female patient
was being treated with 6 mg/day of risperidone and 15 mg/day of
clorazepate. She developed depressive symptomatology and 40 mg/day of
fluoxetine was gradually added to her treatment regimen for about 9
months. After the remission of depression, and the discontinuation of
fluoxetine, she experienced an increase in appetite and subsequently
excessive weight gain of 52 kg. Re-administration of fluoxetine did not
reverse the situation. The patient developed diabetes mellitus, which
was successfully controlled with metformin 1700 mg/day. The addition at
first of orlistat 360 mg/day and later of topiramate 200 mg/day has
helped her to lose a significant part of the weight gained (30 kg).
Conclusion: The case suggests a probable association between the
remission of depressive symptomatology and weight gain in a
schizophrenic patient
Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report
Abstract Background The use of atypical antipsychotics in schizophrenic patients has been associated with a risk of weight gain. Similarly, recovery from depression is often followed by improved appetite, greater food intake and potential increase in weight. Case presentation A Caucasian 33-year-old schizophrenic female patient was being treated with 6 mg/day of risperidone and 15 mg/day of clorazepate. She developed depressive symptomatology and 40 mg/day of fluoxetine was gradually added to her treatment regimen for about 9 months. After the remission of depression, and the discontinuation of fluoxetine, she experienced an increase in appetite and subsequently excessive weight gain of 52 kg. Re-administration of fluoxetine did not reverse the situation. The patient developed diabetes mellitus, which was successfully controlled with metformin 1700 mg/day. The addition at first of orlistat 360 mg/day and later of topiramate 200 mg/day has helped her to lose a significant part of the weight gained (30 kg). Conclusion The case suggests a probable association between the remission of depressive symptomatology and weight gain in a schizophrenic patient.</p